证券代码：002688 证券简称：金河生物 公告编号：2023-053 金河生物科技股份有限公司 2023年第一次临时股东大会决议的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 特别提示： 1、本次股东大会无否决提案的情形。 2、本次股东大会没有涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 金河生物科技股份有限公司（以下简称"公司"）2023 年第一次临时股东 大会通知于 2023 年 8 月 1 日在《上海证券报》、《证券时报》、《证券日报》、 《中国证券报》及巨潮资讯网（www.cninfo.com.cn）以公告方式发出。 1、召开时间 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2023 年 8 月 21 日的交易时间，即 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳 证券交易所互联网投票系统投票的具体时间为：2023 年 8 月 21 日上午 9:15 至 下午 15:00 期间的任意时间。 2、股权登记日：2023 年 8 月 15 日 3、现场会议召开地点：内蒙古自治 ...

金河生物科技股份有限公司投资者关系活 动记录表 编号：2023-005 | --- | --- | --- | |------------------------|----------------------------------------|------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关系活动类别 | □媒体采访 □新闻发布会 □路演活动 | □业绩说明会 | | | 现场参观 | | | | □其他（请文字说明其他活动内容） | | | | 公司董事会秘书 路漫漫 | | | | 公司财务总监 牛有山 | | | | 金河佑本生物制品有限公司总经理 | 王家福 | | | 公司证券事务代表 | 李鹏程 | | | 中信建投证券股份有限公司 | 王明琦 | | | 中信建投证券股份有限公司 | 王晓芳 | | | 中信建投证券自营 | 叶天鸣 | | | 国海证券股份有限公司 | 熊子兴 | | | 华泰证券股份有限公司 | 曹鸣东 | | | 浙商基金管理有限公司 | 贾腾 | | | 浙商基 ...

4、法玛威生物在国内和国外市场的疫苗产品占比是 多少？ 公司的美国子公司法玛威疫苗产品在美国及其它地 区和中国的销售比例约为 35:65，谢谢！ 5、《十四五生物经济发展规划》对公司的主业-动保 业务有哪些积极影响？ 尊敬的投资者，您好！国家发展改革委 2022 年印发 《"十四五"生物经济发展规划》（简称"《规划》"）， 《规划》明确了生物经济的发展领域，顺应"以治病为中 心"转向"以健康为中心"的新趋势，二是顺应"解决温 饱"转向"营养多元"的新趋势，三是顺应"追求产能产 效"转向"坚持生态优先"的新趋势，四是顺应"被动防 御"转向"主动保障"的新趋势，加强国家生物安全风险 防控和治理体系建设。《规划》的提出对公司未来业务发 展有积极的促进作用，公司一直专注动保领域，以保护动 物健康，增进人类幸福为己任，公司兽用化药、兽用疫苗 及环保业务等都与《规划》的未来发展领域吻合，公司会 金河生物科技股份有限公司投资者关系活 动记录表 编号：2023-004 | 投资者关系活动类别 | □特定对象调研 □分析师会议 □媒体采访 | | | --- | --- | --- | | | 业绩说明会 | | | | □ ...

证券代码：002688 证券简称：金河生物 公告编号：2023-039 金河生物科技股份有限公司 关于参加内蒙古辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 为进一步加强与投资者的互动交流，金河生物科技股份有限公司（以下简 称"公司"）将参加由内蒙古证监局、内蒙古上市公司协会与深圳市全景网络有 限公司联合举办的"2023 年内蒙古辖区上市公司投资者集体接待日活动"，现将 相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，活动时间为 2023 年 6 月 9 日（周五）15:30-17:00。届时公 司高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计 划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢 迎广大投资者踊跃参与！ 特此公告。 金河生物科技股份有限公司 董 事 会 2023 年 6 月 5 ...

金河生物科技股份有限公司投资者关系活 动记录表 编号：2023-003 | --- | --- | --- | |------------------------|--------------------------------------------------|----------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关系活动类别 | □媒体采访 □新闻发布会 □路演活动 | □业绩说明会 | | | 现场参观 | | | | □其他（请文字说明其他活动内容） | | | | 公司证券事务代表 | 李鹏程 | | | 公司证券事务中心 | 孙雪茹 | | | 公司证券事务中心 | 王三毛 | | | 公司证券事务中心 | 杨婧楠 | | | 国海证券股份有限公司 | 熊子兴 | | | 华泰证券股份有限公司 | 曹鸣东 | | | 华西证券股份有限公司 | 张伟明 | | 活动参与人员 | 华西证券股份有限公司中国长城资产管理股份有限公司 | 蔺培文 李晓东 | | | 中国长城资产管理股 ...

金河生物科技股份有限公司投资者关系活动记录表 编号：2023-002 您好！金霉素如果在牛羊的适用上获批，其他厂家 的金霉素也会受益，这对金霉素产品的市场空间拓展是 一个利好，蛋糕做大了，大家都可以多分一点，是行业 的好事，岂不美哉！ 5、董事长，您就像一个老大哥，弟弟说一句，如果单 纯的把股票，看做是一个融资的渠道，那是大错特错 了，我真心的希望，您能重视资本市场，对企业发展 的真正意义，希望金河一切都好，长风破浪会有时， 直挂云帆济沧海。 回复： 公司上市是公司发展的一个里程碑，公司从此走上 了高速发展的轨道，先后并购了杭州荐量疫苗公司、美 国普泰克疫苗公司，进入了动物疫苗领域。上市解决了 公司融资难的问题，为公司未来的发展打开了空间，提 供了足够的资金支持，公司融资是为了把企业做大做 | | | | □特定对象调研 | □分析师会议 | | | --- | --- | --- | --- | --- | --- | | 投资者关系活动类 | □媒体采访  业绩说明会 | | | | | | 别 | □新闻发布会 □路演活动 | | | | | | | □现场参观 | | | | | | 活动参与人员 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 527,286,393.92, representing a 1.45% increase compared to CNY 519,765,405.51 in the same period last year[5] - Net profit attributable to shareholders was CNY 36,920,074.20, marking a 16.20% increase from CNY 31,771,635.03 year-on-year[5] - Basic earnings per share rose to CNY 0.0473, up 16.22% from CNY 0.0407 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 527,286,393.92, an increase of 1.0% compared to CNY 519,765,405.51 in Q1 2022[28] - Net profit for Q1 2023 was CNY 40,439,624.37, a decrease of 6.0% from CNY 43,496,662.89 in Q1 2022[29] - The total comprehensive income for the first quarter of 2023 was CNY 34,595,261.09, a decrease from CNY 41,952,788.32 in the previous year, representing a decline of approximately 17.5%[30] Cash Flow - The net cash flow from operating activities decreased by CNY 58,163,894.77, a decline of 158.00% compared to the previous year[15] - The net cash flow from operating activities was negative at CNY -21,352,026.70, compared to a positive CNY 36,811,868.07 in the same period last year[33] - The cash outflow from operating activities totaled CNY 505,294,806.80, compared to CNY 483,337,561.32 in the previous year, an increase of about 4.5%[33] - The company did not report any cash inflow from investment activities, resulting in a net cash flow from investment activities of CNY -60,603,411.71, similar to the previous year's CNY -64,565,989.89[33] - The net cash flow from financing activities was CNY 80,682,022.28, significantly higher than CNY 21,158,538.49 in the previous year, marking an increase of approximately 281.5%[33] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,573,098,902.44, reflecting a 1.50% increase from CNY 4,505,582,532.92 at the end of the previous year[5] - The company's total liabilities increased to CNY 2,112,802,128.28, up from CNY 2,080,365,862.98 at the beginning of the year[26] - The company's cash and cash equivalents decreased to CNY 421,418,848.00 from CNY 491,367,885.89 at the beginning of the year, representing a decline of 14.2%[24] - The total cash and cash equivalents at the end of the period were CNY 408,318,743.68, down from CNY 492,542,177.26, a decrease of about 17.1%[33] Shareholder Information - The total number of common shareholders at the end of the reporting period was 31,495[19] - The largest shareholder, Inner Mongolia Jinhai Holdings Co., Ltd., holds 30.98% of the shares, amounting to 241,758,670 shares[19] - The company plans to implement a restricted stock incentive plan to attract and retain talent, approved by the board on April 21, 2023[22] Operational Metrics - Total operating costs for Q1 2023 were CNY 492,684,043.93, up 3.0% from CNY 477,748,716.72 in the same period last year[28] - Revenue from sales of goods and services received cash of CNY 450,600,293.78, down from CNY 483,989,302.99, indicating a decrease of about 6.5%[32] - Accounts receivable increased to CNY 431,826,292.69, up 5.4% from CNY 409,497,970.35 at the start of the year[24] - Inventory rose to CNY 733,229,854.64, an increase of 8.5% compared to CNY 675,908,511.03 at the beginning of the year[25] - Short-term borrowings increased to CNY 1,270,276,378.56, up 1.9% from CNY 1,246,476,832.69 at the start of the year[26] Other Financial Metrics - The weighted average return on equity increased by 0.36 percentage points to 1.65% compared to 1.29% in the previous year[5] - The company reported a significant increase in interest income, which rose by CNY 1,413,270.37, a 501.81% increase year-on-year[10] - Credit impairment losses increased by CNY 1,571,788.96, representing a 421.29% rise due to extended payment terms from some downstream customers[10] - Other comprehensive income attributable to shareholders decreased by CNY 3,670,579.37, a reduction of 282.29% due to foreign exchange fluctuations[14] - Cash received from investment decreased by ¥30,300,000.00, a decline of 100.00% compared to the previous year, due to the absence of similar business activities[16] - Cash received from other financing activities decreased by ¥1,250,000.00, also a decline of 100.00%, primarily due to the previous year's bank refund of loan deposits[16] - Cash paid for financing activities decreased by ¥70,100,570.65, a reduction of 99.29%, as there were no similar business activities this period[16] - Dividend payments increased by ¥4,713,005.48, an increase of 53.37%, mainly due to the rise in average borrowing amounts[16] - The net effect of exchange rate changes on cash and cash equivalents was an increase of ¥735,386.23, a growth of 35.51% year-on-year[17] - Research and development expenses for Q1 2023 were CNY 15,311,156.03, a decrease of 20.4% from CNY 19,280,982.50 in Q1 2022[29]

Financial Performance - The company's operating revenue for 2022 was ¥2,122,705,317.42, representing a 2.15% increase compared to ¥2,077,988,730.16 in 2021[6]. - The net profit attributable to shareholders decreased by 19.63% to ¥75,543,369.47 in 2022 from ¥93,992,380.84 in 2021[6]. - The basic earnings per share fell by 28.35% to ¥0.0968 in 2022, down from ¥0.1351 in 2021[6]. - The total assets increased by 10.85% to ¥4,505,582,532.92 at the end of 2022, compared to ¥4,064,525,859.70 at the end of 2021[6]. - The company's cash flow from operating activities decreased by 18.63% to ¥124,471,194.04 in 2022 from ¥152,978,505.57 in 2021[6]. - The weighted average return on equity decreased by 1.72 percentage points to 3.09% in 2022 from 4.81% in 2021[6]. - The company reported a net profit of -¥26,914,451.49 in Q4 2022, contrasting with profits in the first three quarters[23]. - The company reported a net profit attributable to shareholders of 75.54 million yuan, a decrease of 19.63% compared to the previous year[40]. - The overall revenue for the reporting period increased by CNY 16.83 million, a growth of 2.34% compared to the same period last year[49]. - The net profit for the reporting period decreased by CNY 8.53 million, a decline of 33.60% year-on-year[49]. Revenue Breakdown - Revenue from veterinary chemical drugs was 983.93 million yuan, a decrease of 7.71%, accounting for 46.35% of total revenue[40]. - Revenue from veterinary biological products increased by 13.19% to 330.17 million yuan, making up 15.55% of total revenue[40]. - The environmental business saw a revenue increase of 25.07%, reaching 107.58 million yuan, which accounted for 5.07% of total revenue[40]. - The revenue from the agricultural processing industry increased by CNY 55.02 million, a growth of 10.76% year-on-year[55]. - Domestic sales accounted for 65.61% of total revenue, increasing by 7.84% compared to the previous year[56]. - Direct sales revenue reached CNY 1,578,151,290, a year-on-year increase of 29.06%[57]. - The revenue from Pharmgate Inc. increased by CNY 88.06 million, a growth of 22.88% compared to the previous year[52]. - The revenue from the environmental business increased by CNY 28.04 million, representing an 18.51% growth compared to the previous year[51]. Cost and Expenses - The company's operating costs reached 1,508.91 million CNY, a year-on-year increase of 5.75%, with veterinary chemical drugs accounting for 46.90% of total operating costs[43]. - The gross profit margin decreased by 2.42 percentage points compared to the previous year due to the increase in operating costs outpacing revenue growth[43]. - The total cost of raw materials for veterinary chemical drugs was approximately 400.69 million, accounting for 56.61% of the total operating costs, showing a slight decrease of 0.18% compared to 2021[63]. - The total sales expenses increased by 6.70% to approximately 130.72 million in 2022, compared to 122.51 million in 2021[68]. - Research and development expenses rose by 13.89% to approximately 82.28 million in 2022, compared to 72.25 million in 2021, reflecting increased investment in vaccine projects and new product development[68]. Market and Competition - The veterinary medicine industry is experiencing increased concentration, with the top 31 companies accounting for 80.4% of total sales in the biological products sector[29]. - The company is facing intensified competition and opportunities in the veterinary medicine market due to regulatory changes and increased foreign investment[30]. - The company is actively expanding into the pet medicine sector, with plans to increase product variety and scope in the future[33]. - The company is focusing on strategic adjustments in product structure to enhance product value and expand business scale[46]. Research and Development - The company has a strong emphasis on research and development, with four major technology platforms for vaccine production and significant advancements in product upgrades[37]. - R&D investment increased by 39.78% to ¥122,010,847.05 in 2022, representing 5.75% of operating revenue[71]. - The number of R&D personnel rose to 252, a 4.13% increase from 2021, with a notable increase in PhD holders by 20%[71]. - The company is focusing on new product development in veterinary vaccines, with several new products expected to be launched in the coming years[33]. Corporate Governance - The company maintains independent operations and governance, with no interference from controlling shareholders in decision-making processes[126]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with governance standards[126]. - The company has established a robust financial management system, including independent accounting and tax reporting[130]. - The company complies with all relevant laws and regulations regarding corporate governance, with no significant discrepancies noted[127]. Environmental Responsibility - The company adheres to various environmental standards, including GB13271-2014J for boiler emissions and GB37823-2019 for pharmaceutical industry emissions[172]. - The company has implemented real-time monitoring of emissions for various pollutants, ensuring adherence to environmental standards[176]. - The company has established a zero discharge wastewater project, ensuring that treated water meets the required pollution discharge standards[176]. - In 2022, the company invested CNY 1.353 million in environmental governance facilities and paid CNY 0.6981 million in environmental protection tax[178]. Future Outlook - The company plans to continue focusing on product development and market expansion to mitigate the impact of market fluctuations[58]. - The company aims to become a technology-driven, leading animal health company within the next 5-10 years[115]. - The company anticipates a revenue growth target of 20% for the next fiscal year, driven by new product launches and market penetration strategies[89]. - The company plans to enhance its supply chain efficiency, targeting a 15% reduction in operational costs by 2024[137].

证券代码：002688 证券简称：金河生物 公告编号:2023-013 金河生物科技股份有限公司 关于举行2022年年度报告网上业绩说明会的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）定于2023年5月10日（星 期三）下午15:00至17:00在全景网举办2022年度业绩说明会，本次年度业绩说 明会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平 台"（https://ir.p5w.net）参与本次年度业绩说明会。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 9 日 15:00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问 题征集专题页面。敬请广大投资者通过全景网系统提交您所关注的问题，便于 公司在业绩说明会上对投资者普遍关注的问题进行回答，提升此次业绩说明会 的针对性。此次活动交流期间，投资者仍可登陆活动界面进行互动提问。 欢迎广 ...

Group 1: Company Overview - The company, Jinhe Biological, has significant sales in both domestic and international markets, with foreign market revenue accounting for 50,983.09 million in 2014, representing a substantial portion of its main business income [1] - The main products are used as feed additives to promote animal production and prevent diseases, and as purified hydrochloride for treating animal diseases [3] Group 2: Product Characteristics - The key features of feed-grade gold mycin include: (1) mature production technology with high efficacy and relatively low cost; (2) broad antibacterial spectrum effective against both Gram-negative and Gram-positive bacteria; (3) no cross-use in humans and animals, avoiding cross-resistance; (4) high safety with low-dose long-term use not causing drug residues; (5) minimal compatibility issues with other feed additives or veterinary drugs [3] Group 3: Strategic Acquisitions - The acquisition of Panfield's operating assets aims to utilize its sales channels to strengthen the company's market position and serve as a strategic development reserve for future expansion [4] Group 4: Future Development Goals - The company envisions becoming a world-leading animal health product enterprise, focusing on consolidating its advantages in biological fermentation and drug feed additives, while actively developing new products in the field of novel veterinary biological products [4]